Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.06.19
Views: 212
Rating:

Prof Philippe Moreau - Chu Nantes, Nantes, France

Prof Philippe Moreau presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the part 1 results of the CASSIOPEIA study.

The addition of daratumumab increased the depth of response and the PFS with acceptable safety and the favourable benefit-risk profile supports the use of D-VTd in transplant-eligible NDMM.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation